NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Topas Therapeutics

Topas Therapeutics

Private
HamburgHealthcare & Life Scienceshttps://topas-therapeutics.com/

Last Round

Series B

Jul 29, 2021

Total Funding Raised

$110.75M

Company Overview

Topas Therapeutics is a biotechnology company that develops nanoparticle-based therapeutics to induce antigen-specific immune tolerance for the treatment of autoimmune diseases, allergies, and anti-drug antibodies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immune tolerancenanoparticle therapyautoimmune diseaseimmunotherapyantigen-specific toleranceliver-directed therapybiotech drug discoverybiopharmaclinical-stage biotechprecision immunologydrug developmentimmune modulationceliac disease treatmentpemphigus vulgarisplatform biology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Topas Therapeutics Comparables

Compare Topas Therapeutics with similar companies based on industry and business-model similarity.

Topas Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Anokion
90%
Imcyse
86%
Cour Pharma
85%

Topas Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BJul 29, 2021
Series BOct 19, 2020
Series ANov 2, 2017
Series AMar 22, 2016

Key People

Founding team and executive leadership

Hugo Fry

Chief Executive Officer

Executive Team

Klaus Martin

CEO

Executive Team

Christian Schroeter

Chief Operating Officer & Managing Director

Executive Team

Topas Therapeutics Investors

Notable investors and investment history

Topas Therapeutics investors
InvestorRounds
BioMedPartnersSeries B
GimvSeries A, Series B
Epidarex CapitalSeries A, Series B
Vesalius Biocapital PartnersSeries B
Boehringer Ingelheim Venture FundSeries A, Series B
EMBL VenturesSeries A, Series B

Topas Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Topas Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Topas Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHamburg
Employee Range21
Year Founded2013
Last FundingJul 29, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.